Cereno Scientific submits application for the start of clinical Phase II study
Cereno Scientific has today submitted its application for clinical trial to the Russian authorities regarding the company’s Phase II study with the drug candidate CS1. The company intends to start the study during the first half of 2020. Soon, an application will also be submitted to the authorities in Bulgaria.
“It is pleasing that all the hard work together with our partners has resulted in us being able to submit the application during the second quarter this year instead of during the third quarter which was the initial plan,” says Cereno Scientific’s CEO Sten R. Sörensen.
The aim of the Phase II study is to show the drug candidate CS1’s preventive effect against the formation of blood clots after surgery. The drug candidate has the potential to redefine the preventive treatment against the formation of blood clots by enhancing the body’s own clot-busting system instead of inhibiting the blood’s coagulation ability.
The Phase II study will be conducted in collaboration with the Russian clinical research organization OCT Group. The study will be conducted at approximately 30 clinics in Russia and Bulgaria and will be performed on patients undergoing orthopedic surgery where the risk of blood clots increases during surgery.
For further information, please contact:
Daniel Brodén – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on May 22, 2019.